Subcutaneous · GLP-1 / GIP dual
CT-388
7 trials in this molecule. Source: ClinicalTrials.gov, as of July 1, 2026.
Trials
7
Active
5
Recruiting
2
Completed
2
Sites
187
Countries
16
Endpoints
169
Composite endpoints
2
Distinct sites and countries across this molecule's trials. A site running several of its trials counts once, matching the map.
Development
Where the program stands
Trials by phase
Phase 1
2
Phase 2
3
Phase 3
2
Trials by status
Not yet recruiting
2
Recruiting
2
Active, not recruiting
1
Completed
2
Evidence coverage
What this asset has been measured on
Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.
Weight & body composition
60
Glycemic / diabetes
35
Cardiometabolic biomarkers
33
Patient-reported / QoL
22
Safety / tolerability / PK
16
Other (unclassified)
2
Renal / kidney
1
Most-measured metrics
Top 20 metrics across this asset's endpoints
Body weight, % changeWeight
13
PGI, changePRO/QoL
8
HbA1c, changeGlycemic
7
Body weight, absolute change (kg)Weight
6
≥5% weight-loss respondersWeight
5
Waist circumference, changeWeight
5
Fasting glucose, changeGlycemic
5
BMI, changeWeight
5
Treatment-emergent AEs (any)Safety/PK
4
HbA1c <6.5% achievementGlycemic
3
LDL-C, changeBiomarker
3
HDL-C, changeBiomarker
3
Triglycerides, changeBiomarker
3
Systolic BP, changeBiomarker
3
Non-HDL cholesterol, changeBiomarker
3
VLDL, changeBiomarker
3
Total cholesterol, changeBiomarker
3
Free fatty acids, changeBiomarker
3
Diastolic BP, changeBiomarker
3
hs-CRP, changeBiomarker
3
Trials
Programs for this asset
Every trial for this molecule, with the same search, filters, and sort as the Trials tab.
⌘K
7 of 7